Clinical trial · Observational
Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer
Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma
NCT00947102CI-TRIAL-00003017GEMSTHERunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Tubular Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pancreatic tubular adenocarcinoma
- description
- Patients with pancreatic tubular adenocarcinoma
- interventionNames
- Other: Observation
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * ECOG performance status 0-2 at the time of inclusion * Following R0 or R1 pancreatic tubular adenocarcinoma resection Exclusion Criteria: * Pregnancy * Serious comorbidity
References
Publications (0)
Data not yet available
No reference posted for this study.